Score Overview
See the full market ranking โ
Kala Pharmaceuticals Inc fundamental performance
Between 2020 and 2025, revenue declined from $ 6M to $ 0.00 and net income went from -$ 104M to -$ 26M. Revenue increased in 0 of those 5 years; net income in every one.
Kala Pharmaceuticals Inc currently holds a 5-year HDB Score of 5.7 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 0.88 | โ |
1 Year2025-08-12 | $ 372.00 | -99.76% |
5 Years2021-08-12 | $ 7.8K | -99.99% |
All Time2017-07-20 | $ 46.23K | -100.00% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | All Time2017-07-20 |
|---|---|---|---|---|
| Price | $ 0.88 | $ 372.00 | $ 7.8K | $ 46.23K |
| Return | โ | -99.76% | -99.99% | -100.00% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 0.00 | -$ 19M | $ 8M |
| 2025 | $ 0.00 | -$ 26M | $ 7M |
| 2024 | $ 0.00 | -$ 38M | $ 51M |
| 2023 | $ 0.00 | -$ 42M | $ 50M |
| 2022 | $ 3M | -$ 44M | $ 70M |
| 2021 | $ 11M | -$ 142M | $ 92M |
| 2020 | $ 6M | -$ 104M | $ 153M |
| 2019 | $ 6M | -$ 94M | $ 85M |
| 2018 | $ 0.00 | -$ 66M | $ 170M |
| IPO2017 | $ 0.00 | -$ 42M | $ 114M |
Explore beyond KALA
You're looking at Kala Pharmaceuticals Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score โ 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
